Association Between N-Acetyltransferase 2 Polymorphism and Antituberculosis Drug-Induced Liver Injury Risk: A Meta-Analysis

Sitong Liu,Xin Yang,Xiang Tong,Yao Ma,Zhipeng Yan,Hong Fan

DOI: https://doi.org/10.1183/1393003.congress-2017.pa3036

IF: 24.3

2017-01-01

European Respiratory Journal

Abstract:Background: Antituberculosis drug-induced liver injury (ATDILI) is a great threat to the control of tuberculosis (TB). Isoniazid (INH) is the major drug responsible for ATDILI and the most important metabolic pathway of INH is acetylation by hepatic enzyme N-acetyltransferase 2 (NAT2). Studies have been conducted to explore the association between NAT2 gene polymorphisms and ATDILI risk but the results were controversial. Objective: To systematically investigate the association between NAT2 gene polymorphisms and the risk of ATDILI. Methods: We searched databases including PubMed, EMBASE, the Cochrane Library, CNKI and Wanfang Data up to December 2016. Case-control studies comparing TB patients with ATDILI with those without ATDILI to evaluate the association between NAT2 polymorphism and ATDILI risk were included. Odds ratio with 95% CI was calculated to evaluate the strength of association. Results: A total of 29 studies involving 1 382 cases and 5 967 controls were included. Overall, NAT2 slow acetylators were significantly associated with increased risk of ATDILI compared with fast and intermediate acetylators（odds ratio: 3.08，95％CI：2.44 - 3.88，P﹤0.000 01）. Significant results were also found in subgroup analyses stratified by ethnicity, INH dosage and diagnostic criteria of ATDILI. Conclusion: The slow acetylator genotype of NAT2 may be associated with increased risk of ATDILI. Detection of NAT2 genotype may be beneficial for the prevention of ATDILI. More studies with large scale and high quality are needed to verify the above conclusion, especially for the patients treated with INH alone or combination therapy including lower dosage of INH.